Fate Therapeutics, Inc. (FATE): Price and Financial Metrics

Fate Therapeutics, Inc. (FATE)

Today's Latest Price: $45.57 USD

1.89 (-3.98%)

Updated Oct 28 10:20am

Add FATE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

FATE Stock Summary

  • Fate Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 9.63% of US listed stocks.
  • With a price/sales ratio of 308.3, Fate Therapeutics Inc has a higher such ratio than 98.46% of stocks in our set.
  • As for revenue growth, note that FATE's revenue has grown 62.38% over the past 12 months; that beats the revenue growth of 91.85% of US companies in our set.
  • Stocks that are quantitatively similar to FATE, based on their financial statements, market capitalization, and price volatility, are DNLI, AUTL, NKTR, ASND, and PRQR.
  • Visit FATE's SEC page to see the company's official filings. To visit the company's web site, go to www.fatetherapeutics.com.

FATE Stock Price Chart Interactive Chart >

Price chart for FATE

FATE Price/Volume Stats

Current price $45.57 52-week high $51.10
Prev. close $47.46 52-week low $12.59
Day low $45.31 Volume 52,108
Day high $46.50 Avg. volume 1,009,024
50-day MA $39.79 Dividend yield N/A
200-day MA $32.03 Market Cap 3.96B

Fate Therapeutics, Inc. (FATE) Company Bio

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. The company was founded in 2007 and is based in San Diego, California.

FATE Latest News Stream

Event/Time News Detail
Loading, please wait...

FATE Latest Social Stream

Loading social stream, please wait...

View Full FATE Social Stream

Latest FATE News From Around the Web

Below are the latest news stories about Fate Therapeutics Inc that investors may wish to consider to help them evaluate FATE as an investment opportunity.

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress

Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with…

GlobeNewswire | August 5, 2020

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 5:30 p.m. ET to report its second quarter 2020 financial results and provide a corporate update. In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 8295527. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be availa...

Yahoo | July 29, 2020

Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players

Vertex (VRTX), the inventor of the new cystic fibrosis wonder drug Trikafta, is a shining star amongst biotech and pharmaceuticals for 2020. On a background of strong fundamentals, with forecasted EBITDA growth of 51.29% in the coming year just to name a few, investors have demonstrated an expectation of extraordinary...

Zach Bristow on Seeking Alpha | July 28, 2020

Could Fate Therapeutics Be a Millionaire-Maker Stock?

Thanks to its powerful platform that enables the efficient mass production of high-impact and high-complexity cellular therapies for cancers and immune disorders, its manufacturing technology licensing revenues alone could be a gold mine. Historically, gathering non-induced stem cells required a donation of human cord blood, making them both expensive to produce and variable from donor to donor, in terms of their cellular properties. Manufacturing iPSCs in small numbers without a human donor isn't new, but the company's innovation is to genetically engineer and culture its iPSCs at scale by generating homogenous cell lines that can be cloned or expanded indefinitely without additional donations.

Yahoo | July 26, 2020

Read More 'FATE' Stories Here

FATE Price Returns

1-mo 12.52%
3-mo 44.21%
6-mo 71.38%
1-year 204.61%
3-year 903.74%
5-year 935.68%
YTD 132.86%
2019 52.53%
2018 109.98%
2017 143.43%
2016 -25.52%
2015 -33.00%

Continue Researching FATE

Here are a few links from around the web to help you further your research on Fate Therapeutics Inc's stock as an investment opportunity:

Fate Therapeutics Inc (FATE) Stock Price | Nasdaq
Fate Therapeutics Inc (FATE) Stock Quote, History and News - Yahoo Finance
Fate Therapeutics Inc (FATE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8412 seconds.